CCL22 and Alzheimer disease: In one clinical study on the human subjects with mild to moderate AD, resveratrol significantly reduced cerebrospinal fluid (CSF) MMP9 levels and increased macrophage-derived chemokine (MDC), IL-4, and FGF-2 levels (Trial Registration: ClinicalTrials.gov NCT01504854) [71].